Sunday, December 30, 2007

Stems of Hope for Treating Incurable Diseases

Stems of Hope for Treating Incurable Diseases
The Future of Things - USA
... as well as to researchers developing stem cells techniques for treatment of other diseases. Multiple Sclerosis (MS) and Amytrophic Lateral Sclerosis ...
See all stories on this topic

Stems of Hope for Treating Incurable Diseases

Thursday, December 27, 2007 - Einat Rotman
Home >> News >> Medicine
http://www.tfot.info/news/1080/stems-of-hope-for-treating-incurable-diseases.html

Two Professors at the Hadassah University Hospital in Jerusalem have succeeded in improving the condition of MS and ALS patients by using stem cells transplants. The researchers extracted stem cells from each patient's bone marrow, cultured them, and then injected them into the patients' spine. The encouraging results of this small clinical study may give hope to those who suffer from these incurable diseases, as well as to researchers developing stem cells techniques for treatment of other diseases.

Submit item to: Del.icio.us Add to: Del.icio.us Digg Add to: Digg StumbleUpon Add to: StumbleUpon Reddit Add to: Reddit Slashdot Add to: Slashdot
Multiple Sclerosis (MS) and Amytrophic Lateral Sclerosis (ALS) are diseases related to the nervous system that currently do not have a cure. MS is the most common neurodegenerative disease. It is a chronic autoimmune inflammatory disease in which an individual’s immune system attacks the central nervous system (CNS), gradually destroying the myelin layers that surround and electrically insulate specific parts of neurons (nerve cells). The myelin layers are important because they enable neural impulses to propagate along the neurons at a high speed. Although the CNS is able to recruit stem cells of remyelinating cells (named oligodendrocytes), these cells are somehow inhibited in repeatedly attacked areas. For this reason, repeated attacks of the immune system can lead to severe impairment of the neural signals and to scarring of the damaged portion of the neuron. MS symptoms depend on the location of the multiple lesions’ occurrence in the CNS. These neurological deficits are progressively accumulated, leading to functional sphincter, sensor, and motor deficiencies. The patient's vision and balance are also damaged.

Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's Disease) is one of the most common neuromuscular diseases worldwide. It is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the CNS that control voluntary muscle movement. As motor neurons degenerate and die, neural signaling to the muscles ceases, resulting in muscle weakness, atrophy, and twitches throughout the body. Patients may ultimately lose their ability to control all voluntary movements except of the eyes. The cause of ALS is not known, and no cure has been found for the disease.

Mesenchymal stem cells are found in the bone marrow and are multipotent - they can differentiate into a variety of cell types, including CNS cells (such as oligodendrocyte-like cells), if cultured in the right conditions. They have also been shown to be able to migrate into the brain. These features make autologous (self) bone marrow transplants, on which the treatment developed at Hadassah University Hospital was based, a possible method for treating various neural diseases.

Professor Dmitrius Karussis, a Senior Neurologist at Hadassah and the Director of the new Multiple Sclerosis Center, worked in collaboration with the University of Athens, and with Professor Shimon Slavin, the Former Director of the Department of Bone Marrow Transplantation (BMT) and the BMT Laboratory at Hadassah. The scientists successfully isolated mesenchymal stem cells from the patients' bone marrow, cultured them under special conditions, and generated over 50 million stem cells within two months. The mesenchymal cells were marked so that the scientists could track them and verify that they reach the intended destination in the patient's body. The cells were then transplanted by a lumbar injection into the patient's spinal cord (into the spinal fluid of the CNS). Each patient served as his/her own bone marrow donor.

According to Professor Karussis, the effectiveness of stem cells was initially studied in laboratory animals, where it was found that stem cells from bone marrow can reduce cerebral damage and improve the animal's functioning. During the past two years Professor Karussis has conducted clinical trials with 9 patients suffering from multiple sclerosis and with 16 patients suffering from ALS. "Most of the patients who underwent this process report an improvement in their condition," Professor Karussis said. The purpose of this initial trial was to identify undesired effects of the procedure. So far, no major safety issues have been encountered. However, a controlled larger scale clinical trial should be conducted in order to establish the safety and efficacy of the treatment.
Even more hope for MS - using
virtual reality to improve walking
Directed to differentiate into specific cell types, stem cells offer the possibility of a renewable source of replacement cells and tissues to treat a variety of diseases. A number of stem cell therapies already exist, particularly bone marrow transplants that are used to treat leukemia. Medical researchers expect stem cell technologies to treat a wider variety of diseases in the future, including cancer, Parkinson's and Alzheimer's diseases, spinal cord injuries, strokes, heart disease, diabetes and arthritis. The clinical trial in Hadassa is supporting this approach, giving patients suffering from various diseases a hope for effective treatments or even cures.

TFOT recently published a comprehensive article about stem cells, covering their biological origin, applications and ethical issues. We also covered another stem cell therapy research that demonstrated the differentiation of human stem cells into heart muscle cells, and a different approach for the creation of tissues, which was demonstrated by an artificial vascular system developed in Cornell University.

Hadassah’s press release of the experimental stem cell treatment is available here.

Related News What Helps HIV Penetrate White Blood Cells?

Professor Dimitrios Karussis
(Credit: Hadassah
Medical Organization)
Stem-cells


Professor Dimitrios Karussis (Credit: Hadassah Medical Organization)

Professor Dimitrios Karussis
(Credit: Hadassah
Medical Organization)


Stems of Hope for Treating Incurable Diseases

Intensive Training Post-spinal Cord Injury Can Stimulate Repair In Brain And Spinal Cord
Intensive rehabilitation training for patients with spinal cord injuries can stimulate new branches growing from severed nerve fibers, alongside compensatory changes in the brain, say Canadian researchers.

The Science Of Shivering Revealed By OHSU Researchers
Researchers at Oregon Health & Science University's Neurological Sciences Institute have uncovered the system that tells the body when to perform one of its most basic defenses against the cold: shivering.

Montel pushes for 'living well'
Sun-Sentinel.com - Fort Lauderdale,FL,USA
BY CARLEY DRYDEN | Los Angeles Daily News December 30, 2007 Montel Williams is 51, has six-pack abs, a new wife and multiple sclerosis. ...
See all stories on this topic

Inflamed Anti-Inflammatory Contract Revised
Motley Fool - USA
The European market is fairly wide open since Elan's (NYSE: ELN) and Biogen Idec's (Nasdaq: BIIB) Tysabri was denied a label expansion. ...
See all stories on this topic

NBC 30 Women Against MS Luncheon raises more than $90000
Stamford Plus Magazine - Stamford,CT,USA
The NBC 30 WAMS Luncheon was chaired by Simsbury resident Maureen Jessen, 45, who was diagnosed with primary progressive MS in 2001. ...
See all stories on this topic

China trip gives St. Charles man hope
Chicago Daily Herald - Chicago,IL,USA
Research suggests cord blood stem cells are particularly useful in treating auto-immune diseases, such as multiple sclerosis, juvenile diabetes and lymphoma ...
See all stories on this topic

Snorting a Brain Chemical Could Replace Sleep

By Alexis Madrigal 12.28.07 | 12:00 AM


http://www.wired.com/science/discoveries/news/2007/12/sleep_deprivation

In what sounds like a dream for millions of tired coffee drinkers, Darpa-funded scientists might have found a drug that will eliminate sleepiness.

A nasal spray containing a naturally occurring brain hormone called orexin A reversed the effects of sleep deprivation in monkeys, allowing them to perform like well-rested monkeys on cognitive tests. The discovery's first application will probably be in treatment of the severe sleep disorder narcolepsy.

The treatment is "a totally new route for increasing arousal, and the new study shows it to be relatively benign," said Jerome Siegel, a professor of psychiatry at UCLA and a co-author of the paper. "It reduces sleepiness without causing edginess."

Orexin A is a promising candidate to become a "sleep replacement" drug. For decades, stimulants have been used to combat sleepiness, but they can be addictive and often have side effects, including raising blood pressure or causing mood swings. The military, for example, administers amphetamines to pilots flying long distances, and has funded research into new drugs like the stimulant modafinil (.pdf) and orexin A in an effort to help troops stay awake with the fewest side effects.

The monkeys were deprived of sleep for 30 to 36 hours and then given either orexin A or a saline placebo before taking standard cognitive tests. The monkeys given orexin A in a nasal spray scored about the same as alert monkeys, while the saline-control group was severely impaired.

The study, published in the Dec. 26 edition of The Journal of Neuroscience, found orexin A not only restored monkeys' cognitive abilities but made their brains look "awake" in PET scans.

Siegel said that orexin A is unique in that it only had an impact on sleepy monkeys, not alert ones, and that it is "specific in reversing the effects of sleepiness" without other impacts on the brain.

Such a product could be widely desired by the more than 70 percent of Americans who the National Sleep Foundation estimates get less than the generally recommended eight hours of sleep per night (.pdf).

The research follows the discovery by Siegel that the absence of orexin A appears to cause narcolepsy. That finding pointed to a major role for the peptide's absence in causing sleepiness. It stood to reason that if the deficit of orexin A makes people sleepy, adding it back into the brain would reduce the effects, said Siegel.

"What we've been doing so far is increasing arousal without dealing with the underlying problem," he said. "If the underlying deficit is a loss of orexin, and it clearly is, then the best treatment would be orexin."

Dr. Michael Twery, director of the National Center on Sleep Disorders Research, said that while research into drugs for sleepiness is "very interesting," he cautioned that the long-term consequences of not sleeping were not well-known.

Both Twery and Siegel noted that it is unclear whether or not treating the brain chemistry behind sleepiness would alleviate the other problems associated with sleep deprivation.

"New research indicates that not getting enough sleep is associated with increased risk of cardiovascular disease and metabolic disorders," said Twery.

Still, Siegel said that Americans already recognize that sleepiness is a problem and have long treated it with a variety of stimulants.

"We have to realize that we are already living in a society where we are already self-medicating with caffeine," he said.

He also said that modafinil, which is marketed as Provigil by Cephalon and Alertec in Canada, has become widely used by healthy individuals for managing sleepiness.

"We have these other precedents, and it's not clear that you can't use orexin A temporarily to reduce sleep," said Siegel. "On the other hand, you'd have to be a fool to advocate taking this and reducing sleep as much as possible."

Sleep advocates probably won't have to worry about orexin A reaching drugstore shelves for many years. Any commercial treatment using the substance would need approval from the Food and Drug Administration, which can take more than a decade.

A nasal spray of a key brain hormone cures sleepiness in sleep-deprived monkeys. With no apparent side effects, the hormone might be a promising sleep-replacement drug.
Photo: Flickr/Mayr
The image “file:///C:/Documents%20and%20Settings/Bill/My%20Documents/jokes/george%20bush%20videos/1guiliani/crash%20and%20burn/sleepdep_500px.jpg” cannot be displayed, because it contains errors.

Brain Evolution and Why it is Meaningful Today to Improve Our Brain Health

Over the last months, thanks to the traffic growth of SharpBrains.com (over 100,000 unique visitors per month these days, THANK YOU for visiting today and please come back!), a number of proactive book agents, publishers and authors have contacted us to inform us of their latest brain-related books. We have taken a look at many books, wrote reviews of The Dana Guide to Brain Health book review and Best of the Brain from Scientific American, and interviewed scientists such as Judith Beck, Robert Emmons and James Zull.

Now we are launching a new Author Speaks Series to provide a platform for leading scientists and experts writing high-quality brain-related books to reach a wide audience. We are honored to start the series with an article by Larry McCleary, M.D, former acting Chief of Pediatric Neurosurgery at Denver Children's Hospital, and author of The Brain Trust Program: A Scientifically Based Three-Part Plan to Improve Memory, Elevate Mood, Enhance Attention, Alleviate Migraine and Menopausal Symptoms, and Boost Mental Energy (Perigee Trade, 2007).

Without further ado, let's enjoy Dr. McCleary's article:

Brain Evolution and Why it is Meaningful Today to Improve Our Brain Health

You may feel overwhelmed by the stream of seemingly contradictory suggestions regarding the best way to maintain mental clarity as you age. Based on an analysis of seminal factors in the development of modern brain anatomy, I believe it is possible to make some very compelling recommendations for growing big brains, enhancing their function, and making them resistant to the aging process. These may be loosely categorized as factors pertaining to the mental or physical attributes of the brain. Although they are not truly independent entities, such a conceptualization provides a basis for the generation of brain healthy prescriptions. Diet, physical exercise, and stress reduction enhance neuronal resilience. Sleep and mental stimulation are vital for cognitive ability, learning, and memory.

Diet: Follow a modern shore-based/marine diet including seafood in its most general sense, non-starchy vegetables of all colors, berries, and eggs. Other sources of lean protein containing long-chain omega 3 fatty acids such as free range beef, chicken, bison, or elk are nutritious alternatives.

Physical exercise (Think ‘fight or flight’ activity.): Include all types. Aerobic activities such as swimming, bicycling, walking, or hiking for promotion of vascular health and weight control; resistance training for promotion of neurotrophic factors, naturally occurring compounds that make brain cells more resistant to aging, such as IGF-1 (Insulin-like growth factor-1) and BDNF (Brain-derived neurotrophic factor); and balance, coordination, and agility training such as ping-pong, balance beam, trampoline, and jumping rope to enhance cognitive speed and motor skills.

Stress Control: From an evolutionary perspective, stressors (such as meeting a cave bear) and intense physical activity (running or fighting) were brief in duration and usually occurred together. Modern stressors (psychological or emotional stress) tend to be unremitting and are generally uncoupled from the physical (fight or flight) component, meaning stress develops without any associated physical activity. Such intense physical pursuits are now called exercise. Not surprisingly, exercise is a perfect physiologic antidote for stress due to its beneficial impact on cortisol (the ‘stress’ hormone) and blood pressure and should be incorporated into any program of stress reduction.

Adequate sleep: The body needs rest, but the brain requires sleep. Acute or chronic sleep deprivation causes devastating short and long-term consequences to brain anatomy (synaptic loss) and function (memory and learning difficulties). Off-line information processing and memory consolidation are additional sleep-related benefits.

Mental stimulation: Brain-training, a cognitively challenging lifestyle, novelty, and socialization are vital for the promotion of neuronal plasticity and neurogenesis (the formation of new nerve cells and neuronal connections), the enhancement of specific brain functions such as memory, and the development of cognitive reserve –additional mental processing potential that may be brought online when needed.

The combination of these recommendations, each of which was instrumental in the transformation from primitive to modern nervous systems, provides a template for the most logical approach for enhancing mental function and resisting neurodegeneration as we travel through life.

The Evolutionary Rationale

The human brain clearly has the genetic potential for dramatic expansion. This was illustrated about 1,500,000 years ago. Enlargement from 900 grams to almost 1300 grams required less than a million years to complete – a mere speck on the evolutionary timeline. Why and how it happened are open questions. What remains undisputed are the magnitude of the change and the impact it had on human capabilities. The rapid volumetric explosion primarily involved the frontal lobe region, a portion of the brain that, until recently, was referred to as the ‘silent’ brain because of its relative lack of any discernable functionality. The frontal lobes are now viewed as the ‘conductor of the orchestra’ because they have been recognized as being responsible for articulating the ‘big picture’ and coordinating other brain regions, as needed, to execute the ‘game plan.’ The Prefrontal cortex (PFC), the most anterior portion of the frontal cortex, has dense connections with all the other regions it oversees. It is generally considered the most plastic cortical region because its synapses are continually being torn down and reconfigured in response to real-time experiences. Plasticity allows the brain to ‘think on its feet.’ Expansion of PFC enabled the cognitive preeminence of modern day humans over all non-human primates. The plasticity of the PFC and its massive connectivity with other brain regions rely entirely on the production and maintenance of point-to-point nerve cell connections, or synapses.

In addition to being a thinking machine, the brain is also a flesh and blood organ that must comply with the laws of metabolism and physiology. Insight into both its ‘mental’ and ‘physical’ properties is vital for comprehending key aspects of brain health and function. Much has been written about the facilitation of brain growth by cognitively demanding tasks such as tool use and hunting. However, there is a component of circular reasoning in this argument. For it to participate in such mentally demanding endeavors, the brain would have relied on the prior existence of sophisticated neuronal circuitry. I suggest a nutritional basis for the dramatic cerebral expansion, with enhanced functionality (such as development of tool use and hunting strategy) being the natural responses of a larger, more plastic organ to novelty and environmental challenges. The common link between the evolutionary cerebral expansion and modern brain health/function resides in the massive wiring demands inherent in both processes. This marked amplification in neuronal connectivity is made possible by the enhanced production of synaptic membranes (nerve cell membranes in the regions of points of nerve cell contact).

How was it possible to fuel the production of major increases in neuronal number and synaptic density? This required the concordant expression of genetic potential (likely driven, in part, by the provision of an uninterrupted energy supply) and proper nutritional content - meaning high, sustained caloric and nutrient density. Just as a certain level of fat mass is a prerequisite for expansion of the female body to support a successful pregnancy, a persistent supply of nutrient dense calories is essential for brain expansion. In times of frequent starvation, this was a substantial nutritional demand. To fully appreciate how energetically expensive brains are, consider that modern brains comprise about 2.3% of the body mass, yet consume almost one quarter of the available energy. Newborn brains utilize fully 75% of the body’s energy!

What type of brain-building diet might have been accessible 1.5 million years ago that didn’t require the cognitive demands inherent in hunting? One solution would be a ‘shore-based’ diet. This means foraging for life forms such as mollusks, crustaceans, eggs, spawning fish, frogs, and contiguous plant life readily available along lake shores or river banks. In a warm clime it would have provided a year-round, high quality diet abundant in calories, fat and protein. It also supplied long-chain omega 3 fatty acids (including DHA), the building blocks of electrically active membranes in neurons and photoreceptor cells.

Big brains must also synthesize abundant cholesterol and other components of nerve cell membranes. This requires a water-soluble source of appropriate building blocks. Ketone bodies (acetoacetate and β-hydroxybutyrate) generated naturally from partially burned fat were, and continue to be, an ideal energy source for the brain while simultaneously providing key precursors for synthesis of nerve cell membranes and synapses. These facilitated the anatomic expansion of the brain, which provided the additional neuronal circuitry that made the learning of hunting skills a possibility.

Hence, what was compulsory for explosive brain expansion of the species is as vital today for optimal brain function and plasticity. It is the ongoing ability to produce high levels of the most functional sites of nerve cells – the synaptic membranes. Appropriate assemblies of nerve cells, as determined by their connections (synapses), provide the basis for the functional attributes we enjoy today. Stress reduction, mental stimulation and proper sleep enhance their resistance to the aging process.

---This article was written by Larry McCleary, M.D, for SharpBrains.com's Author Speaks Series. Dr. McCleary (blog) is a former acting Chief of Pediatric Neurosurgery at Denver Children's Hospital. He is trained and has practiced as a pediatric neurosurgeon and has completed post-graduate training in theoretical physics. His scientific publications span the fields of metabolic medicine, tumor immunology, biotechnology and neurological disease. He is the author of The Brain Trust Program: A Scientifically Based Three-Part Plan to Improve Memory, Elevate Mood, Enhance Attention, Alleviate Migraine and Menopausal Symptoms, and Boost Mental Energy (Perigee Trade, 2007).

http://www.sharpbrains.com/blog/2007/12/27/brain-evolution-and-why-it-is-meaningful-today-to-improve-our-brain-health/

Friday, December 28, 2007

Research promises to reduce suffering from MS

Research promises to reduce suffering from MS
Akron Beacon Journal Wed, 26 Dec 2007 8:12 AM PST
Barely 15 years ago, doctors could do nothing to change the course of multiple sclerosis, the disabling neurological disease that strikes in the prime of adulthood. German firm develops tech to treat multiple sclerosis
The Post - Lahore,Punjab,

MS patients receive adult stem cells in Israeli study
Israel 21C - Cupertino,CA,USA
Shimon Slavin, the recently retired head of Hadassah's bone marrow unit, extracted stem cells from the hip bone marrow of 26 multiple sclerosis (MS) and ...
See all stories on this topic

MultiCell Technologies To Increase Focus on Therapeutic Candidates
FOX News - USA
"MultiCell's lead drug candidate, MCT-125, for the treatment of primary multiple sclerosis-related fatigue, has demonstrated efficacy in human clinical ...
See all stories on this topic

German firm develops tech to treat multiple sclerosis
The Post - Lahore,Punjab,Pakistan
Around 2.5m patients are registered worldwide of multiple sclerosis out of which around 10000 exists in Pakistan. The only therapeutic success achieved so
http://thepost.com.pk/IsbNews.aspx?dtlid=135843&catid=17

The Post - Lahore,Punjab,Pakistan
Around 2.5m patients are registered worldwide of multiple sclerosis out of which around 10000 exists in Pakistan. The only therapeutic success achieved so ...
http://thepost.com.pk/IsbNews.aspx?dtlid=135843&catid=17

SCS signs ally in diabetes research

The Herald - Glasgow,Scotland,UK
Stem Cell Sciences (SCS), the pioneering Edinburgh University spin-out, has signed a research agreement with a "major pharmaceutical company" to help ...
See all stories on this topic

China trip gives St. Charles man hope
Chicago Daily Herald - Chicago,IL,USA
The St. Charles man, who has battled multiple sclerosis for 31 years, reports a drastic reduction in symptoms since going to China in August for umbilical ...

http://www.dailyherald.com/story/?id=103080&src=5

Tuesday, December 25, 2007

Stem cell hope for immune disease
Online - International News Network - Islamabad,Pakistan
ISLAMABAD: Common immune system
disorders, such as multiple sclerosis and arthritis,
could one day be treatable with bone marrow
transplants, ...
See all stories on this topic

Stem cell hope for immunedisease ONLINE - International News Network

ISLAMABAD: Common immune system disorders, such as multiple sclerosis and arthritis, could one day be treatable with bone marrow transplants, research suggests.

Currently, the procedure is reserved for life-threatening disorders because chemotherapy or radiotherapy is needed before a transplant can be done.

But a protein may do the same job without dangerous side-effects, a mouse study published in Science suggests. However, the technique is not yet ready for testing in humans.

The purpose of a bone marrow transplant is to infuse the body with healthy adult stem cells which are able to form fresh blood and immune cells.

In order for the new blood-forming stem cells to take hold, the faulty cells in the bone marrow must first be destroyed, but the aggressive therapies used can cause severe side effects, such as brain damage, increased risk of cancer or infertility.

A person with an autoimmune disease such as multiple sclerosis has a defective immune system in which immune cells attack the person’s own body.

Treatment with a bone marrow transplant would give the patient an immune system that might not attack the body, but this could only be done if the technique was less dangerous.

A team from Stanford University in the US found that injecting mice with antibodies which latch on to specific proteins on the surface of blood-forming stem cells, destroyed the cells without harming the mice.

Blood-forming stem cells transplanted into the mice were then able to take up residence in the bone marrow and set up a new blood and immune system.

However, the barriers are still significant, the researchers said, as the work was done on a particular group of mice that are a poor mimic for the human immune system.

And it remains to be seen whether the same molecule on human blood-forming stem cells would be the right one to use.

"It is essentially a surgical strike against the blood-forming stem cells," said study author Dr Irving Weissman, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

He added that he believed the hurdles to translating the research into humans could be overcome.

Dr Laura Bell, research communications officer at the MS Society, said: "Stem cell studies are an important avenue of research which hold promise in terms of treatments for MS.

"This early stage study is interesting and we look forward to seeing how the work translates into studies in people with MS."
http://www.onlinenews.com.pk/details.php?id=121103

Biogen Idec Abandons Sale, Loses $6 Billion in Value (Update3) Bloomberg.com: Exclusive

By Luke Timmerman

http://www.bloomberg.com/apps/news?pid=20601109&sid=aaL7qO37DDsw&refer=home

Dec. 13 (Bloomberg) -- Biogen Idec Inc., the maker of the multiple sclerosis drug Tysabri, lost more than $5 billion in market value after saying it plans to remain independent.

The Cambridge, Massachusetts, developer of drugs for cancer as well as MS said its business plan is working and it will no longer pursue a sale. Biogen fell $17.97, or 24 percent, to $57.91 at 4 p.m. New York time in Nasdaq stock market composite trading. Pfizer Inc., the world's biggest drugmaker, and Sanofi- Aventis SA had been considered potential acquirers.

Big drugmakers may have been turned off by complications stemming from Biogen's partnership with Genentech Inc. to market the cancer drug Rituxan and with Elan Corp. on Tysabri, said Eric Schmidt, an analyst with Cowen & Co. in New York. The price may also have been too high, he said.

``Perhaps there just weren't many big pharma companies interested in paying as much as AstraZeneca did for biotech assets like MedImmune at $58 a share,'' Schmidt said in a telephone interview. He rates the stock ``neutral,'' and said the stock market's reaction was ``appropriate.''

London-based AstraZeneca Plc bought MedImmune in June for about $14.7 billion.

Biogen repeated its financial forecast from September, saying Tysabri may generate at least $2.8 billion annually by 2010, and the company plans to introduce four new products or existing drugs for new diseases during that time. Biogen said it can produce 15 percent compound annual sales growth, and 25 percent compound annual growth in earnings per share.

Dependent on Tysabri

The projections may be overly optimistic, Schmidt said. Biogen depends on Tysabri, which was pulled from the market in February 2005 when it was linked to a rare, fatal brain infection. If the drug continues to grow, Biogen could achieve its goals. If more infections appear, ``it could be a zero,'' Schmidt said.

Biogen said it remains optimistic. The company has 15 medicines in the second phase of clinical testing or later, and it expects to see results from eight large trials by the end of 2008, said Naomi Aoki, a company spokeswoman.

James Mullen, 48, Biogen's chief executive officer, and all other executives will remain in their current roles, Aoki said. The company has 4,300 employees worldwide and has no plans for any layoffs, Aoki said.

``We're going to continue on as we had before, and we still feel we have extremely strong growth prospects,'' Aoki said.

Pipeline Drugs

Besides Tysabri, Biogen has built a pipeline of five other drugs in development for MS. Each fights the nerve disorder in a unique way and may add $1 billion in annual sales apiece if successful in clinical trials, Jason Kantor, an analyst with RBC Capital Markets in San Francisco, said in an interview last week.

Multiple sclerosis, a neurological condition that can harm speech, vision and movement, affects an estimated 2.5 million people worldwide. The market for MS drugs exceeded $5.5 billion in 2006 and is expected to double by 2013, according to market- research firm Frost & Sullivan in New York.

One of Biogen's two drugs in late-stage testing is vying to be the first oral pill against MS. Biogen researchers believe the compound, BG-12, works by damping down inflammation, while also protecting healthy cells. It would be used for relapsing, remitting MS, which affects about 85 percent of patients, according to the National MS Society, based in New York.

Another approach, also in final patient testing, uses the cancer drug Rituxan against primary progressive MS, a condition in which the disease worsens over time and for which there is no effective treatment.

Business as Usual

Biogen may have a hard time getting back to work, analysts said.

``It's very hard to announce a company is for sale, and then say `oops, we're calling it all off and going back to business as usual,''' Geoffrey Porges, an analyst with Sanford Bernstein & Co. in New York, said in an interview last week. Employees have been looking for other jobs or waiting for a buyout, he said. ``It's so disruptive.''

The company put itself up for sale, and hired Goldman, Sachs & Co. and Merrill Lynch & Co. in October after billionaire investor Carl Icahn expressed interest in buying the company for $23 billion.

The idea was short-lived. Icahn made his interest known before the company announced his bid Oct. 12, and he withdrew it that same day, Biogen's Aoki said. The company later approached Icahn again, and he declined to make an offer, Aoki said.

Biogen approached all the major pharmaceutical companies individually and gave each an opportunity to review Biogen's operations, Aoki said. In the end, Biogen ``did not receive any definitive offers'' and decided its current strategy ``will result in attractive value for stockholders,'' the company said in the statement yesterday.

Biogen, founded in 1978, trails Amgen Inc., Genentech, Genzyme Corp. and Gilead Sciences Inc. by sales among biotechnology companies.

To contact the reporter on this story: Luke Timmerman in San Francisco at ltimmerman@bloomberg.net

Last Updated: December 13, 2007 16:36 EST

Biogen Idec Abandons Sale, Loses $6 Billion in Value (Update1)
Bloomberg - USA
Another approach, also in final patient testing, uses the cancer drug Rituxan against primary progressive MS, a condition in which the disease worsens over ...
See all stories on this topic


Liberal NH newspaper slams Romney
United Press International - USA
"There was a time that he supported stem cell research and cited his own wife's multiple sclerosis in explaining his thinking; such research, he reasoned, ...
See all stories on this topic





UC Irvine scientists find new way to sort stem cells

Method could speed the production of future stem cell therapies

Irvine, Calif., Dec. 20, 2007 � UC Irvine scientists have found a new way to sort stem cells that should be quicker, easier and more cost-effective than current methods. The technique could in the future expedite therapies for people with conditions ranging from brain and spinal cord damage to Alzheimer�s and Parkinson�s diseases.

The method uses electrodes on a tiny, inch-long glass slide to sort cells by their electric charges and has been used in cancer research. The stem cell field suffers from a lack of tools for identifying and sorting cells. This important discovery could add a new tool to current sorting methods, which generally require expensive, bulky equipment.

�For therapeutic purposes, we want stem cells to turn into specific cell types once they have been transplanted. The trick to doing this is identifying beforehand which cells will become the desired cell type, such as a neuron,� said Lisa Flanagan, lead author of the study and a stem cell biologist at UCI. �We have discovered a new, potentially better way to do this by focusing on the electric properties of the cells.�

This study appears online Dec. 20 in the journal Stem Cells.

The technique used by the scientists, called dielectrophoresis, is based on the premise that different types of cells have different electric properties. Stem cells that are destined to become neurons, for example, have a different electric charge than stem cells that will become astrocytes, another type of brain cell. The scientists discovered that the cells react differently when electric fields are applied. At one frequency, a neuron will be attracted to an electrode but an astrocyte will not, and at a different frequency, an astrocyte will be attracted but a neuron will not.

Identifying and sorting stem cells is important when creating stem cell-based therapies. Without a purification process, stem cell transplantations can cause tumors or be rejected by the body�s immune system.

In this study, the scientists wanted to identify and collect stem cells that were destined to become neurons, which are cells in the brain and spinal cord that process and transmit information. Neurons that die as a result of injury or disease do not regenerate, which is why people with neuronal loss suffer problems such as paralysis and memory loss. Scientists believe that stem cell transplantations might be able to restore part of the lost function.

With the goal of identifying future neurons, UCI engineers built a tiny device using a glass slide to perform the dielectrophoresis. First, scientists place unsorted mouse stem cells on one side of the device. The cells then float in sugar water through a tiny channel past electrodes set to a particular frequency. At a certain frequency, stem cells destined to become neurons will stick to the electrodes while other cells pass by. The cells that stick then can be removed and grouped together, potentially for use in a therapy.

Currently, stem cells most often are separated using a machine called a fluorescence-activated cell sorter (FACS). FACS machines, which use lasers to detect the light scattering and fluorescent characteristics of the cells, can weigh hundreds of pounds and cost $500,000 or more. The UCI-designed dielectrophoresis device is just a fraction of the size and cost. The two devices could be used to complement each other to create ultra pure stem cell populations.

�Once the mold is created, these sorts of devices can cost just pennies to make,� said Ed Monuki, senior author and UCI developmental biologist. �You could have many for every member of your lab and it wouldn�t be prohibitively expensive.�

A strong collaborative partnership between UCI biologists and engineers made this discovery possible. With input from biologists, engineers built the device in UCI�s Integrated Nanosystems Research Facility. �This represents truly an interdisciplinary effort that expands the horizon in both biology and engineering fields,� said Abraham Lee, a study co-author affiliated with the Department of Biomedical Engineering in The Henry Samueli School of Engineering at UCI.

###

The biologists are affiliated with the UCI Department of Pathology and Laboratory Medicine, the Department of Developmental and Cell Biology, and the Sue and Bill Gross Stem Cell Research Center. A hub for stem cell research in Southern California, UCI is raising money for a new building that will house its stem cell researchers, the core laboratory, training facilities and research space. UCI is applying to the California Institute for Regenerative Medicine for a facilities grant to build the structure.

Jente Lu, Lisen Wang, Steve Marchenko and Noo Li Jeon of UCI also worked on this study, which was supported by the Roman Reed Spinal Cord Injury Research Fund of California.

About the University of California, Irvine: The University of California, Irvine is a top-ranked university dedicated to research, scholarship and community service. Founded in 1965, UCI is among the fastest-growing University of California campuses, with more than 27,000 undergraduate and graduate students and about 1,800 faculty members. The second-largest employer in dynamic Orange County, UCI contributes an annual economic impact of $3.7 billion. For more UCI news, visit www.today.uci.edu.

Television: UCI has a broadcast studio available for live or taped interviews. For more information, visit www.today.uci.edu/broadcast.

News Radio: UCI maintains on campus an ISDN line for conducting interviews with its faculty and experts. The use of this line is available free-of-charge to radio news programs/stations who wish to interview UCI faculty and experts. Use of the ISDN line is subject to availability and approval by the university.

UCI maintains an online directory of faculty available as experts to the media. To access, visit www.today.uci.edu/experts.

For UCI breaking news, visit www.zotwire.uci.edu.

NOTE TO EDITORS: Photo available at http://today.uci.edu/news/release_detail.asp?key=1712


http://www.eurekalert.org/pub_releases/2007-12/uoc--uis122007.php

Stem cell hope for immune disease
Online - International News Network - Islamabad,Pakistan
ISLAMABAD: Common immune system
disorders, such as multiple sclerosis and arthritis,
could one day be treatable with bone marrow
transplants, ...
See all stories on this topic

Stem cell hope for immune

disease

ONLINE - International News Network
ISLAMABAD: Common immune system disorders, such as multiple sclerosis and arthritis, could one day be treatable with bone marrow transplants, research suggests.

Currently, the procedure is reserved for life-threatening disorders because chemotherapy or radiotherapy is needed before a transplant can be done.

But a protein may do the same job without dangerous side-effects, a mouse study published in Science suggests. However, the technique is not yet ready for testing in humans.

The purpose of a bone marrow transplant is to infuse the body with healthy adult stem cells which are able to form fresh blood and immune cells.

In order for the new blood-forming stem cells to take hold, the faulty cells in the bone marrow must first be destroyed, but the aggressive therapies used can cause severe side effects, such as brain damage, increased risk of cancer or infertility.

A person with an autoimmune disease such as multiple sclerosis has a defective immune system in which immune cells attack the person’s own body.

Treatment with a bone marrow transplant would give the patient an immune system that might not attack the body, but this could only be done if the technique was less dangerous.

A team from Stanford University in the US found that injecting mice with antibodies which latch on to specific proteins on the surface of blood-forming stem cells, destroyed the cells without harming the mice.

Blood-forming stem cells transplanted into the mice were then able to take up residence in the bone marrow and set up a new blood and immune system.

However, the barriers are still significant, the researchers said, as the work was done on a particular group of mice that are a poor mimic for the human immune system.

And it remains to be seen whether the same molecule on human blood-forming stem cells would be the right one to use.

"It is essentially a surgical strike against the blood-forming stem cells," said study author Dr Irving Weissman, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

He added that he believed the hurdles to translating the research into humans could be overcome.

Dr Laura Bell, research communications officer at the MS Society, said: "Stem cell studies are an important avenue of research which hold promise in terms of treatments for MS.

"This early stage study is interesting and we look forward to seeing how the work translates into studies in people with MS."
http://www.onlinenews.com.pk/details.php?id=121103

Biogen Idec Abandons Sale, Loses $6 Billion in Value (Update3) Bloomberg.com: Exclusive

By Luke Timmerman

http://www.bloomberg.com/apps/news?pid=20601109&sid=aaL7qO37DDsw&refer=home

Dec. 13 (Bloomberg) -- Biogen Idec Inc., the maker of the multiple sclerosis drug Tysabri, lost more than $5 billion in market value after saying it plans to remain independent.

The Cambridge, Massachusetts, developer of drugs for cancer as well as MS said its business plan is working and it will no longer pursue a sale. Biogen fell $17.97, or 24 percent, to $57.91 at 4 p.m. New York time in Nasdaq stock market composite trading. Pfizer Inc., the world's biggest drugmaker, and Sanofi- Aventis SA had been considered potential acquirers.

Big drugmakers may have been turned off by complications stemming from Biogen's partnership with Genentech Inc. to market the cancer drug Rituxan and with Elan Corp. on Tysabri, said Eric Schmidt, an analyst with Cowen & Co. in New York. The price may also have been too high, he said.

``Perhaps there just weren't many big pharma companies interested in paying as much as AstraZeneca did for biotech assets like MedImmune at $58 a share,'' Schmidt said in a telephone interview. He rates the stock ``neutral,'' and said the stock market's reaction was ``appropriate.''

London-based AstraZeneca Plc bought MedImmune in June for about $14.7 billion.

Biogen repeated its financial forecast from September, saying Tysabri may generate at least $2.8 billion annually by 2010, and the company plans to introduce four new products or existing drugs for new diseases during that time. Biogen said it can produce 15 percent compound annual sales growth, and 25 percent compound annual growth in earnings per share.

Dependent on Tysabri

The projections may be overly optimistic, Schmidt said. Biogen depends on Tysabri, which was pulled from the market in February 2005 when it was linked to a rare, fatal brain infection. If the drug continues to grow, Biogen could achieve its goals. If more infections appear, ``it could be a zero,'' Schmidt said.

Biogen said it remains optimistic. The company has 15 medicines in the second phase of clinical testing or later, and it expects to see results from eight large trials by the end of 2008, said Naomi Aoki, a company spokeswoman.

James Mullen, 48, Biogen's chief executive officer, and all other executives will remain in their current roles, Aoki said. The company has 4,300 employees worldwide and has no plans for any layoffs, Aoki said.

``We're going to continue on as we had before, and we still feel we have extremely strong growth prospects,'' Aoki said.

Pipeline Drugs

Besides Tysabri, Biogen has built a pipeline of five other drugs in development for MS. Each fights the nerve disorder in a unique way and may add $1 billion in annual sales apiece if successful in clinical trials, Jason Kantor, an analyst with RBC Capital Markets in San Francisco, said in an interview last week.

Multiple sclerosis, a neurological condition that can harm speech, vision and movement, affects an estimated 2.5 million people worldwide. The market for MS drugs exceeded $5.5 billion in 2006 and is expected to double by 2013, according to market- research firm Frost & Sullivan in New York.

One of Biogen's two drugs in late-stage testing is vying to be the first oral pill against MS. Biogen researchers believe the compound, BG-12, works by damping down inflammation, while also protecting healthy cells. It would be used for relapsing, remitting MS, which affects about 85 percent of patients, according to the National MS Society, based in New York.

Another approach, also in final patient testing, uses the cancer drug Rituxan against primary progressive MS, a condition in which the disease worsens over time and for which there is no effective treatment.

Business as Usual

Biogen may have a hard time getting back to work, analysts said.

``It's very hard to announce a company is for sale, and then say `oops, we're calling it all off and going back to business as usual,''' Geoffrey Porges, an analyst with Sanford Bernstein & Co. in New York, said in an interview last week. Employees have been looking for other jobs or waiting for a buyout, he said. ``It's so disruptive.''

The company put itself up for sale, and hired Goldman, Sachs & Co. and Merrill Lynch & Co. in October after billionaire investor Carl Icahn expressed interest in buying the company for $23 billion.

The idea was short-lived. Icahn made his interest known before the company announced his bid Oct. 12, and he withdrew it that same day, Biogen's Aoki said. The company later approached Icahn again, and he declined to make an offer, Aoki said.

Biogen approached all the major pharmaceutical companies individually and gave each an opportunity to review Biogen's operations, Aoki said. In the end, Biogen ``did not receive any definitive offers'' and decided its current strategy ``will result in attractive value for stockholders,'' the company said in the statement yesterday.

Biogen, founded in 1978, trails Amgen Inc., Genentech, Genzyme Corp. and Gilead Sciences Inc. by sales among biotechnology companies.

To contact the reporter on this story: Luke Timmerman in San Francisco at ltimmerman@bloomberg.net

Last Updated: December 13, 2007 16:36 EST

Biogen Idec Abandons Sale, Loses $6 Billion in Value (Update1)
Bloomberg - USA
Another approach, also in final patient testing, uses the cancer drug Rituxan against primary progressive MS, a condition in which the disease worsens over ...
See all stories on this topic


Liberal NH newspaper slams Romney
United Press International - USA
"There was a time that he supported stem cell research and cited his own wife's multiple sclerosis in explaining his thinking; such research, he reasoned, ...
See all stories on this topic

-----------------------------------------------------------------------------

Liberal N.H. newspaper slams Romney - UPI.com


Published: Dec. 24, 2007 at 7:50 AM
http://www.upi.com/NewsTrack/Top_News/2007/12/24/liberal_nh_newspaper_slams_romney/1931/


CONCORD, N.H., Dec. 24 (UPI) -- Republican presidential hopeful Mitt Romney has been lambasted by a liberal New Hampshire newspaper as someone who "must be stopped."

A Concord Monitor editorial slammed the former Massachusetts governor, calling him "a disquieting figure who sure looks like the next president and most surely must be stopped."

The editorial recalled Romney's advocacy of gay rights in 1994, when he was running against Sen. Edward Kennedy, D-Mass., for the U.S. Senate, and compared that with his current stance.

"These days, he makes a point of his opposition to gay marriage and adoption," it said.

The newspaper also attacked his record on scientific ethics.

"There was a time that he supported stem cell research and cited his own wife's multiple sclerosis in explaining his thinking; such research, he reasoned, could help families like his. These days, he largely opposes it," the editorial said.

Romney campaign spokesman Kevin Madden told CNN the criticisms were taken in stride.

"The Monitor's editorial board is regarded as a liberal one on many issues, so it is not surprising that they would criticize Governor Romney for his conservative views and platform," Madden said.

New Hampshire is the site of the first U.S. president preference primary early next month
http://www.upi.com/NewsTrack/Top_News/2007/12/24/liberal_nh_newspaper_slams_romney/1931/


Early Fine-Tuning Of Neural Connections May Turn Destructive Later In Life

Main Category: Neurology / Neuroscience News
Article Date: 24 Dec 2007 - 0:00 PST


The immune system helps to prune excess connections between neurons in the developing brains of young mice, according to scientists funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). The study, published in the December 14 issue of the journal Cell, sheds critical new light upon a fundamental process, while hinting at a likely mechanism behind neurodegenerative diseases like glaucoma and Alzheimer's disease.

Shortly after birth, the mammalian brain contains vast numbers of connections, or synapses, between neurons - many more than will be needed in adulthood. Scientists have known for years that the developing brain follows a use it or lose it rule: inactive connections are pruned away during childhood and adolescence. However, the molecular mechanism underlying this pruning process has remained one of the biggest mysteries in neurobiology. Now, Dr. Beth Stevens and Dr. Ben Barres of the Stanford University School of Medicine and their colleagues report that a protein used by the immune system to destroy bacteria is also needed by the young brain to target and destroy unwanted synapses.

"From the fetal period through early adulthood, the developing brain is constantly fine-tuning its synaptic connections. These results provide new insight into this vital process," said Dr. Nora Volkow, NIDA director. "Eventually, research like this, into the fundamental mechanisms of brain development, will help us understand why a child's brain is so vulnerable to environmental factors, including addictive drugs."

"The immune system's involvement in sculpting synapses was totally unexpected," added Dr. Barres. The immune protein C1q is among the body's first responders to injury or infection, attaching to dead cells or bacteria and triggering their destruction. Surprisingly, the researchers also found C1q attached to immature synapses in the brains and retinas of young mice. Unlike normal mice, mice missing C1q were unable to eliminate extra synapses as they aged, producing disorganized, abnormal connections in their visual systems.

In collaboration with Dr. Simon John of The Jackson Laboratory, the researchers asked whether diseases like glaucoma could trick C1q into targeting synapses in the adult. They found that although C1q is normally turned off in the nervous systems of mature mice, it reappears during the early stages of glaucoma, when retinal synapses begin to deteriorate. This discovery offers a tantalizing clue to how synapses might be lost in neurodegenerative diseases like Alzheimer's disease and ALS.

"It looks like as soon as something goes wrong, C1q is reactivated," said Dr. Barres. "In the mouse model of human glaucoma, C1q is the earliest sign of disease, appearing well before visible damage to synapses and neurons. We hope that if we block C1q and the immune cascade it triggers, we can block the disease before neurons start to die."

The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world's research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to inform policy and improve practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found on the NIDA home page at http://www.drugabuse.gov .

The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov
http://www.medicalnewstoday.com/articles/91581.php

Monday, December 24, 2007

Stanford researchers find stem cell transplant can grow new immune system

Stanford researchers find stem cell transplant can grow new immune ...
Bizjournals.com - Charlotte,NC,USA
... and Regenerative Medicine. The study will be published in the Nov. 23 issue of Science. A person with an autoimmune disease such as multiple sclerosis ...
See all stories on this topic

Best Stocks for 2008: Elan (ELN) has 'more room to run'
BloggingStocks - USA
"I originally recommended it in June 2005 at $7 after the company withdrew Tysabri, a multiple sclerosis drug, from the US market. After being reapproved by ...
See all stories on this topic

Montel Williams' new book shares secrets of healthy living
The Birmingham News - al.com - Birmingham,AL,USA
When talk show host Montel Williams was diagnosed with multiple sclerosis he thought his life was over. Doctors told him to quit his show, avoid stress and ...
See all stories on this topic

Lilly in Deal with BioMS for MS Drug
From Reuters Health - Dec 18, 2007
NEW YORK (Reuters) - Eli Lilly and Co said on Monday it has entered a deal that gives it exclusive worldwide rights to an experimental multiple sclerosis drug being developed by Canada's BioMS Medical Corp. The drug, MBP8298, is currently in late-stage clinical trials for secondary progressive multiple sclerosis (MS) and in mid-stage trials for relapsing-remitting MS, the companies said.
Read Full Article Article Summary

Lilly in Deal for Rights to BioMS Medical MS Drug - Therapeutics Daily


Reuters Health - Dec. 18, 2007
NEW YORK (Reuters) - Eli Lilly and Co said on Monday it has entered a deal that gives it exclusive worldwide rights to an experimental multiple sclerosis drug being developed by Canada's BioMS Medical Corp.
The drug, MBP8298, is currently in late-stage clinical trials for secondary progressive multiple sclerosis (MS) and in mid-stage trials for relapsing-remitting MS, the companies said.
BioMS Medical will receive an upfront payment of $87 million, potential development and sales milestones up to $410 million and escalating royalties on sales if the drug is approved.
Lilly and BioMS Medical will collaborate on the development of MBP8298 and will share in certain development costs, while Lilly will be responsible for future research and development, manufacturing and marketing, the companies said.
"MBP8298 has shown potential in slowing the progression of secondary progressive MS, and thus may provide an effective therapeutic option for patients with this debilitating disease," Dr William Chin, Lilly's vice president of discovery research and clinical investigation, said in a statement.
"We are also hopeful that MBP8298 may prove beneficial in treating patients with relapsing remitting MS," Chin said. "We intend to fully leverage our expertise in neuroscience to continue the development of this novel molecule."
The deal is expected to be finalized in the first quarter of 2008. Lilly said it expects to take a charge to earnings of about 5 cents per share at closing of the deal.
Lilly said its 2008 pro forma adjusted earnings forecast remains unchanged at $3.85 to $4.00 per share. Including the charge for the transaction with BioMS Medical, Lilly now expects 2008 earnings of $3.80 to $3.95 per share.
Analysts on average expect the company to earn $3.88 per share in 2008, according to Reuters Estimates.
(Reporting by Bill Berkrot, editing by Tim Dobbyn)
http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=1647739&contenttype=sentryarticle&channelID=30

Sunday, December 23, 2007

Advancing on MS: New drugs and hopes for a vaccine

Advancing on MS: New drugs and hopes for a vaccine
Belleville News Democrat - IL, USA
Thirty years ago, a gene variant was linked to MS in about half of patients. The next major genetic advance didn't come until four months ago, ...
See all stories on this topic

Center for Clinical and Translational Science funds eight new ...
The Rockefeller University Newswire - New York,NY,USA
Jan Lunemann, postdoctoral fellow in Christian Münz’s Laboratory of Viral Immunobiology, to test the hypothesis that a cause of multiple sclerosis is an ...
See all stories on this topic

REPRINT:THE 2005 REPORT MITT, MORMONISM, AND THE PRESIDENCY
Blogger News Network - USA
... for stem cell research in 2002, research that could lead to effective treatments for his wife Anne’s multiple sclerosis, to outright opposition in 2005. ...
See all stories on this topic

Taking a punt on C&C and Kingspan
Irish Independent - Dublin,Ireland
Elan's progress will depend on sales of Tysabri for the treatment of MS now that it is back on the market. It's risky but I think it's worth a punt.
See all stories on this topic

Advancing on MS: New drugs and hopes for a vaccine
The San Luis Obispo Tribune Fri, 21 Dec 2007 10:45 AM PST
Barely 15 years ago, doctors could do nothing to change the course of multiple sclerosis, the disabling neurological disease that strikes in the prime of adulthood. Today, six drugs are approved to decrease the periodic immune attacks that underlie MS, another six are in final human testing, and dozens more are in development. Researchers have zeroed in on genetic and environmental risk factors; ...

Bayer HealthCare Awards Grant to Multiple Sclerosis Foundation
PR Newswire (press release) - New York,NY,USA
About Multiple Sclerosis MS is a chronic, progressive disease of the central nervous system. Symptoms of MS vary from person to person and can be ...
See all stories on this topic

Bayer HealthCare Awards Grant to Multiple Sclerosis Foundation

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-18-2007/0004724692&EDATE=
Charitable donation will help fund support programs for people living with
MS

WAYNE, N.J., Dec. 18 /PRNewswire/ -- Bayer HealthCare today announced a
charitable gift of $85,000 to the Multiple Sclerosis Foundation (MSF) to
fund programs that provide aid and support for those living with multiple
sclerosis (MS). The donation, made by the Bayer Foundation, is one of many
each year that funds the programs of advocacy organizations that serve the
needs of people affected by conditions that Bayer HealthCare products
treat.
The MSF offers a variety of support services to improve the quality of
life for people with MS by enhancing comfort, safety and self-sufficiency.
The donation from the Bayer Foundation will help fund the following MSF
programs:
-- Patient Assistance Program - Provide one-time assistance to individuals
with MS who are struggling financially and do not have access to or
qualify for community, state, and national support agencies.
-- Assistive Technology (AT) Program - Educates individuals with MS about
available AT options that can help them function more independently in
daily activities (including computers, mobility devices and vision
aids), and assists in acquiring them.
-- Home Care Grants - Serves as a liaison between people with MS and local
resources to meet their specific caregiving needs, such as personal
hygiene services, light housekeeping, grocery shopping and
transportation to and from appointments.
-- Brighter Tomorrow Grants - Provides goods or services to improve
quality of life, such as eyeglasses, televisions, therapeutic
equipment, mobility devices, and various home modifications.
-- Cooling Program - Because heat aggravates MS symptoms, keeping the body
cool can help people with MS cope with warm weather. This program
offers body cooling items free of charge, including vests, neckties,
wristbands, and hats.
"Patient education and care are the cornerstones of our organization,
and we are grateful for Bayer HealthCare's generosity," said Alan Segaloff,
Executive Director, Multiple Sclerosis Foundation. "This charitable
contribution will help us continue to motivate, educate and empower
individuals with MS and their loved ones."

MS is a chronic, progressive disease of the central nervous system that
causes irreparable nerve damage. There are at least 400,000 Americans with
MS, and every week about 200 new people are diagnosed with the condition.
"We are proud to support and work with patient service groups, such as
the MSF, which work tirelessly to improve the lives of people with MS,"
said Ludger Heeck, Ph.D., Vice President and General Manager, Specialized
Therapeutics, Bayer HealthCare Pharmaceuticals. "This donation reflects our
ongoing commitment to supporting those who are affected by the condition."
The Bayer Foundation is an endowed 501(c)(3) entity and the primary
source for Bayer HealthCare's philanthropic giving throughout the United
States. It supports programs that enhance the quality of life, provide
unique and enriching opportunities that connect diverse groups and ensure
preparedness for tomorrow's leaders.
About Multiple Sclerosis
MS is a chronic, progressive disease of the central nervous system.
Symptoms of MS vary from person to person and can be unpredictable. They
may include: fatigue or tiredness, visual dysfunction in one or both eyes,
weakness in one or more extremities, numbness and tingling in the face,
arms, legs and trunk of the body, spasticity (muscle stiffness), dizziness,
slurred speech and bladder dysfunction.
About the Multiple Sclerosis Foundation
The Multiple Sclerosis Foundation (MSF) is a publicly funded 501(c)(3)
organization that was established in 1986. Headquartered in Fort
Lauderdale, Florida, the MSF is a predominantly service-based organization
that strives to ensure the best quality of life for those coping with MS by
providing comprehensive support and educational programs. The MSF supports
research into the cause and cure of MS, as well as investigations of
various medical and complementary treatment options.
About Bayer HealthCare Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals
unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's
leading, innovative companies in the healthcare and medical products
industry, Bayer HealthCare combines the global activities of the Animal
Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the
U.S., Bayer HealthCare Pharmaceuticals comprises the following business
units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics,
Hematology/Cardiology and Oncology. The company's aim is to discover and
manufacture products that will improve human health worldwide by
diagnosing, preventing and treating diseases.
This news release contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group management. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation,
development or performance of the company and the estimates given here.
These factors include those discussed in our public reports filed with the
Frankfurt Stock Exchange and with the U.S. Securities and Exchange
Commission (including Form 20-F). The company assumes no liability
whatsoever to update these forward-looking statements or to conform them to
future events or developments.
SOURCE Bayer HealthCare Pharmaceuticals
Link to this page:
Link to this page
Back to Topback to top
Related links:
# http://www.berlex.com
www.technorati.com Blogs Linking to this News Release at Technorati
Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2007 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-18-2007/0004724692&EDATE=

It's official: you can't beat a computer at checkers. Here's what we can do…

Stephen Cauchi
December 23, 2007
PREVIOUS winners have included the WMAP probe's mapping of the infant universe and the discovery that there was once water on Mars. But in 2007, the journal Science — which, alongside Nature, is the most prestigious in its field — has awarded breakthrough of the year to advances in understanding the human genome.
In the past year, researchers have linked variations in more than 50 genes to type 1 and 2 diabetes, Crohn's disease, heart disease, breast cancer, restless leg syndrome, glaucoma, multiple sclerosis, rheumatoid arthritis and colorectal cancer.
The link between genes and disease has fuelled the growth of businesses. Depending on how much you're willing to pay — from $2000 to more than $1 million — you can get anything from a quick genome scan to a complete sequencing.
Of course, coupled with the advances in genetics are concerns about ethics. Should an insurance company refuse coverage to a person with a known genetic risk? And what are the costs to a person's peace of mind if they find out they have a predisposition to an incurable disease, even if the risk is slight?
Stem cells from skin cells was Science's "runner-up" discovery. Stem cells have been hailed as the new revolution in medicine, the potential cure for everything from diabetes to cancer. The most pluripotent cells, able to morph into any form of tissue, are embryonic stem cells. But these involve growing and destroying a human embryo, presenting serious ethical issues.
Last month, two groups of researchers — one Japanese, one American — transformed ordinary human skin cells into cells that look and act like embryonic stem cells. "This work represents a tremendous scientific milestone — the biological equivalent of the Wright brothers' first airplane," said Robert Lanza of Advanced Cell Technology, a Massachusetts company in the same field. "It's not practical to use right now, but it might be in a few years. This is truly the Holy Grail — to be able to take a few cells from a patient, say a cheek swab or a few skin cells, and turn them into stem cells in the laboratory."
The other eight discoveries, in no particular order, are:…
http://www.theage.com.au/cgi-bin/common/popupPrintArticle.pl?path=/articles/2007/12/22/1198175413410.html

Friday, December 21, 2007

Patsy's Blog Tells Of Her Experiences Of Multiple Sclerosis, UK

Patsy's Blog Tells Of Her Experiences Of Multiple Sclerosis, UK
A teenager living with multiple sclerosis (MS) will share her experiences with the world after being asked to write an online blog for her local newspaper. Patsy Peebles, 15, will regularly update the Newcastle Evening Chronicle's Purely Patsy blog site with information on how MS affects her schooling, social life, thoughts and feelings in a bid to give hope and support to others in a similar situation.20 Dec 2007

Brave Patsy meets her new Big Brother
ChronicleLive - Newcastle upon Tyne,England,UK
She later became the only person under 18 to try out the trial MS drug Campath. Patsy lives with her parents, Bill and Joanna, sister Anna, 13, ...
See all stories on this topic

Lilly gets worldwide rights to BioMS' multiple sclerosis drug

PharmaBiz
Thursday, December 20, 2007 11:00 IST
Indianapolis
Eli Lilly and Company said it inked a licensing and development agreement with BioMS Medical Corporation, granting Lilly exclusive worldwide rights to BioMS' lead multiple sclerosis (MS) compound, MBP8298.
The compound is currently being evaluated in two pivotal phase III clinical trials in secondary progressive MS (SPMS) and one phase II clinical trial in relapsing-remitting MS (RRMS).
BioMS Medical will receive an upfront payment of $87 million, as well as potential development and sales milestones up to $410 million and escalating royalties on sales commensurate with the current stage of development of the product if MBP8298 is successfully commercialised. BioMS Medical will continue to oversee the current clinical trials. Other terms of the deal were not disclosed.
Under the terms of the agreement, Lilly and BioMS Medical will collaborate on the development of MBP8298 and will also share in certain development costs with Lilly being responsible for future R&D, manufacturing and marketing activities.
"Lilly is pleased to add yet another promising late-stage compound to our portfolio," said Dr. William W. Chin, M.D., vice president, discovery research and clinical investigation, Lilly. "Multiple sclerosis is a disease with significant unmet patient needs. MBP8298 has shown potential in slowing the progression of secondary progressive MS, and thus may provide an effective therapeutic option for patients with this debilitating disease. We are also hopeful that MBP8298 may prove beneficial in treating patients with relapsing remitting MS. We intend to fully leverage our expertise in neuroscience to continue the development of this novel molecule."
The transaction is expected to become effective in the first quarter of 2008, contingent upon clearance under the Hart-Scott-Rodino Anti-Trust Improvements Act, if required. At closing, Lilly would expect a charge to earnings for acquired in-process research and development. The exact amount of the charge has not yet been determined, but is estimated to be $0.05 per share. Lilly's 2008 pro forma adjusted earnings per share guidance remain unchanged at $3.85 to $4.00. On a reported basis, including the charge for this transaction with BioMS Medical, Lilly now expects its 2008 earnings per share to be in the range of $3.80 to $3.95.
"We are very pleased to collaborate with Lilly on the worldwide development of MBP8298," said Kevin Giese, president and CEO, BioMS Medical. "Lilly's well established leadership in the neurology arena and considerable resources, expertise and proven ability to launch first-in-class drugs will help MBP8298 to realize its full development and commercial potential."
MBP8298 is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). MBP8298 is being developed for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system.
The apparent mechanism of action of MBP8298 is the induction or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide delivered periodically by the intravenous route. The potential benefit of MBP8298 for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.
The results of phase II and long-term follow-up treatment of MS patients with MBP8298, published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, MBP8298 has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.
MBP8298 is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01.
Multiple sclerosis (MS) is thought to affect as many as 2.5 million people worldwide, including approximately 75,000 in Canada, 400,000 in the United States and more than 500,000 in Europe. It is a disease that affects more women than men, with onset typically occurring between 20 and 50 years of age. MS is caused by damage to myelin, the protective sheath surrounding nerve fibres in the central nervous system, which interferes with messages from the brain to the body. Symptoms of MS may include vision problems, loss of balance, numbness, difficulty walking and paralysis. Approximately 40 percent of all MS patients have the secondary progressive form of the disease.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.
BioMS Medical is a biotechnology company engaged in the development and commercialisation of novel therapeutic technologies.
http://www.pharmabiz.com/article/detnews.asp?articleid=42113

Lilly gets worldwide rights to BioMS' multiple sclerosis drug
PharmaBiz Wed, 19 Dec 2007 9:32 PM PST
Eli Lilly and Company said it inked a licensing and development agreement with BioMS Medical Corporation, granting Lilly exclusive worldwide rights to BioMS' lead multiple sclerosis (MS) compound, MBP8298.

Patsy's Blog Tells Of Her Experiences Of Multiple Sclerosis, UK
Medical News Today Thu, 20 Dec 2007 5:16 AM PST
A teenager living with multiple sclerosis (MS) will share her experiences with the world after being asked to write an online blog for her local newspaper. [click link for full article]

Bayer HealthCare Awards Grant to Multiple Sclerosis Foundation
Earthtimes - London,UK
"This charitable contribution will help us continue to motivate, educate and empower individuals with MS and their loved ones." MS is a chronic, progressive ...
See all stories on this topic

Biogen drug pipeline makes it a tempting target
International Herald Tribune - France
Another approach, also in final patient testing, uses the cancer drug Rituxan against primary, progressive multiple sclerosis, a condition in which the ...
See all stories on this topic

Addition of antibiotics to MS therapy could slow down progression of the disease
News-Medical-Net Wed, 19 Dec 2007 2:16 PM PST
Researchers from Louisiana State University in the U.S. are suggesting that the addition of antibiotics to standard drug therapy for multiple sclerosis, may slow down the progress of the disease.

Eli Lilly and BioMS Medical announce licensing and development agreement
News-Medical-Net Wed, 19 Dec 2007 1:31 AM PST
Eli Lilly and Company and BioMS Medical Corp. have announced that the two companies have entered into a licensing and development agreement granting Lilly exclusive worldwide rights to BioMS Medical's lead multiple sclerosis (MS) compound, MBP8298.

Conference Report

Highlights of the 132nd Annual Meeting of the American Neurological Association

October 7-10, 2007; Washington, DC

Posted 12/07/2007

Rohit Bakshi, MD, FAAN
Author Information

The American Neurological Association held its 132nd Annual Meeting in Washington, DC, from October 7 to 10. Clinicians and scientists came together to share the latest research data in the field of neurology and neuroscience. Abstracts based on these presentations were published in a special supplement issue of the Annals of Neurology (registration required).

Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune-mediated inflammatory demyelinating multifocal disorder affecting the brain, spinal cord, and optic nerves. The disease affects women more commonly than men and typically presents in early or middle adulthood. Currently available therapies are only partially effective, and patients may continue to experience relapses and progressive disability despite optimal therapies. In patients with MS, physical and occupational rehabilitation therapy is often helpful in promoting recovery after acute relapses and helping patients with chronic deficits to maximize their functional status.

Finkelstein and colleagues[7] tested a computer-based, home-based rehabilitation strategy, known as the Home Automated Telemanagement (HAT) system, in 12 patients with MS. Through HAT, patients reported daily their progress and results of a 12-week prescribed self-delivered exercise/rehabilitation program. The patients' neurologic status and attitudes were assessed at baseline and after the 12-week HAT-facilitated program. Eighty-three percent of patients found HAT "not complicated at all" to use and felt they would most likely or definitely use HAT again. Neurologic status assessed by the Six-Minute Walk Test, Timed 25-Foot Walk, and Berg Balance scale showed statistically significant improvements over the 12 weeks. These data indicate that further study of home telerehabilitation is warranted for its ability to improve functional status in patients with MS.

http://www.medscape.com/viewarticle/565551_1